Rate My Professor Gwo-Tzer Ho

Ho's research centers on the complexities of IBD, including Crohn’s disease and ulcerative colitis, with a focus on gut mucosal healing, mucosal immunology, immune-metabolism, mitochondrial function, and biomarker discovery. His group bridges discovery science to clinical translation using patient-derived organoids, immune cells, multi-omic data, and real-world NHS clinical datasets, involving nearly 1,500 patients in studies over the past five years. Key initiatives include the Scotland-wide MUSIC study on mitochondrial danger signals in IBD and the UK multicentre MARVEL Phase 2 randomized controlled trial of oral mitochondrial antioxidants in ulcerative colitis. Ongoing projects explore macrophage biology, M-cell function, microbiome-immune interactions, fatigue in IBD, metabolic enhancement of gut repair, novel diagnostics like Granzyme B tests (IDXsense project), and PET-MRI imaging for fibrosis (FATE-CD). Ho's work has secured funding from the Leona M. and Harry B. Helmsley Charitable Trust, Jon Moulton Foundation, Wellcome Trust, UKRI/MRC, Chief Scientist Office, and European Research Council. Notable publications include Hegarty et al., 'Tissue resident colonic macrophages persist through acute inflammation and adapt to aid tissue repair' (Mucosal Immunology, 2026); Chuah et al., 'Machine learning approach to dissect the clinical heterogeneity of IBD-associated fatigue' (BMJ Digital Health and AI, 2026); Fandinga et al., 'Patient acceptability of partial enteral nutrition as a concomitant therapy to Adalimumab in adults with active Crohn’s disease – BIOPIC trial' (Annals of Nutrition and Metabolism, 2026); and Halligan et al., 'Patient-led thematic analysis on the impact of living with Inflammatory Bowel Disease' (Crohn’s and Colitis 360, 2025). His contributions have advanced understanding of IBD pathogenesis and therapeutic strategies.